Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer
NCT05223647 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 239
Last updated 2026-01-28
Summary
Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI) prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer (ES SCLC), but the survival benefit is modest. The main aim of this trial is to investigate whether there is a synergistic/additive effect of concurrent thoracic radiotherapy in ES SCLC patients receiving carboplatin/etoposide/durvalumab.
Conditions
- Small-cell Lung Cancer
Interventions
- PROCEDURE
-
Thoracic radiotherapy
30Gy/10 fractions thoracic radiotherapy given between 2nd and 3rd course of chemo-immunotherapy.
- DRUG
-
Chemo-immunotherapy
Four courses of carboplatin/etoposide/durvalumab every 3 weeks followed by durvalumab every 4 weeks until intolerable toxicity, progressive disease leading to a need for other treatment, or until the patient no longer wishes to continue treatment.
Sponsors & Collaborators
-
St. Olavs Hospital
collaborator OTHER -
Haukeland University Hospital
collaborator OTHER -
University Hospital of North Norway
collaborator OTHER -
Alesund Hospital
collaborator OTHER -
Helse Stavanger HF
collaborator OTHER_GOV -
Oslo University Hospital
collaborator OTHER -
Helse Nord-Trøndelag HF
collaborator OTHER -
Helse Fonna
collaborator OTHER -
Drammen sykehus
collaborator OTHER -
University Hospital, Akershus
collaborator OTHER - collaborator OTHER
-
Sahlgrenska University Hospital
collaborator OTHER -
Karolinska University Hospital
collaborator OTHER -
Gävle Hospital
collaborator OTHER -
Sykehuset Innlandet HF
collaborator OTHER -
North Estonia Medical Centre
collaborator OTHER -
Nordlandssykehuset HF
collaborator OTHER -
Landspitali University Hospital
collaborator OTHER -
Lund University Hospital
collaborator OTHER -
University Hospital, Linkoeping
collaborator OTHER -
Norwegian University of Science and Technology
lead OTHER
Principal Investigators
-
Magnus Steigedal, PhD · Department of Clinical and Molecular Medicine, NTNU
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-01-11
- Primary Completion
- 2025-09-04
- Completion
- 2025-09-04
Countries
- Estonia
- Iceland
- Netherlands
- Norway
- Sweden
Study Locations
More Related Trials
-
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
NCT05267392 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer
NCT03585998 ·Status: UNKNOWN ·Phase: PHASE2
-
Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab
NCT05568212 ·Status: RECRUITING ·Phase: PHASE2
-
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
NCT04716946 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study
NCT04392505 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
NCT02352948 ·Status: COMPLETED ·Phase: PHASE3
-
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
NCT05403723 ·Status: SUSPENDED ·Phase: PHASE1
-
Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial
NCT04432142 ·Status: ACTIVE_NOT_RECRUITING
-
Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer
NCT03923270 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
NCT05221840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)
NCT02453282 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)
NCT03319316 ·Status: WITHDRAWN ·Phase: PHASE2
-
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
NCT04092283 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
NCT05617963 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers
NCT04230408 ·Status: COMPLETED ·Phase: PHASE2
-
Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy
NCT05796089 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
NCT04364048 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)
NCT02542293 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer
NCT03540420 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer
NCT03871153 ·Status: TERMINATED ·Phase: PHASE2
-
Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC
NCT04163432 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
NCT04245514 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT03703297 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer
NCT04003246 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC
NCT05092412 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2